🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07208513
Starting soon Observational

Multi-omics Study of Peritoneal Dialysis Effluent to Explore Biomarkers of Peritoneal Fibrosis

NCT07208513 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Jiao Tong University School of Medicine
Phase
Observational
Started
2025-10-20
Last updated
2025-10-06

Condition(s) studied

Peritoneal DialysisPeritoneal Fibrosis

Study summary

Biomarkers of peritoneal fibrosis in patients with peritoneal dialysis were investigated by transcriptomics of exfoliated cells and metabolomics of exfoliated cells in peritoneal dialysis

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients on peritoneal dialysis: a. Age 18-75 years; b. Regular abdominal dialysis due to uremia\> 3 months; c. Signed informed consent 2. Hemodialysis patients: a. Age 18-75 years; b. Due to regular hemodialysis due to uremia\> 3 months old, allogeneic kidney transplantation is planned; c. Signed informed consent 3. Patients with normal renal function: a. Age 18-75 years; b. Proposed elective inguinal hernia repair surgery; c. Signed informed consent. Exclusion Criteria: 1. Patients on peritoneal dialysis: a. History of peritonitis in the past 3 months; b. History of abdominal tumors with peritoneal metastases 2. Hemodialysis patients: a. Previous abdominal dialysis history; b. History of abdominal tumors with peritoneal metastases Patients with normal renal function: a. History of chronic kidney disease; b. History of abdominal tumors with peritoneal metastases

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Renji Hospital Shanghai Shanghai Municipality

More Shanghai Jiao Tong University School of Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07208513 on ClinicalTrials.gov ↗ ← All trials in China